Abstract
Potential savings from biosimilars are a subject of keen interest internationally, with a particular relevance for Canadians. Canada is a relatively high-use and high-price market for biologics and the increased use of biosimilars offers a significant opportunity for cost savings for Canadian payers. Recent policy changes to promote biosimilar switching are expected to result in significant cost reductions for these classes of biologics in Canada, helping to offset the pressure from new higher-cost medicines in coming years. As these initiatives are implemented at the provincial level, Canada offers a unique model to observe the impacts of variations in approach and timing across jurisdictions. The analysis aims to identify potential opportunities in the Canadian biosimilars market in comparison with international practices.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
